Please login to the form below

Not currently logged in
Email:
Password:

Active Biotech

This page shows the latest Active Biotech news and features for those working in and with pharma, biotech and healthcare.

Teva drops laquinimod for most common form of MS after failed trial

Teva drops laquinimod for most common form of MS after failed trial

CONCERTO study showed no disability progression improvements over placebo. Teva and Active Biotech have suffered another setback in their efforts to develop laquinimod for multiple sclerosis and are abandoning the programme. ... Shares in Active Biotech

Latest news

  • Another setback for Teva's laquinimod in MS Another setback for Teva's laquinimod in MS

    Teva and partner Active Biotech have said they will continue to develop multiple sclerosis (MS) candidate laquinimod, despite side effects seen in two late-stage trials. ... Teva and Active Biotech have been through the mill trying to bring laquinimod to

  • MS market set to grow 4% annually

    When it comes to branded medicines, Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063 are the projected

  • Teva backs laquinimod for MS despite CHMP rejection Teva backs laquinimod for MS despite CHMP rejection

    Teva and partner Active Biotech have vowed to continue developing laquinimod as an oral therapy for multiple sclerosis (MS), despite being rejected for approval in the EU. ... Teva and Active Biotech still feel the project has potential.

  • CHMP turns down drugs for MS, cancer and muscular dystrophy CHMP turns down drugs for MS, cancer and muscular dystrophy

    In Teva's response to the decision, the Israeli company said it and partner Active Biotech were committed to the development of laquinimod as a treatment for MS and will request

  • Czech biotech Sotio selects Chiltern International

    Czech biotech Sotio selects Chiltern International. UK CRO will work on late-stage trials for its prostate cancer therapy. ... The trials will assist the biotech company's development of Active Cellular Immunotherapy (ACI), which focuses on cancer and

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    100. Active Biotech (SE). NeoTx (IS). Licence. Tumour Targeting Superantigen ANYARA in phase I for oncology.

  • Pharma deals during December 2012 Pharma deals during December 2012

    European biotech also active. Not all the drug discovery action is in Texas or California, as Evotec (based in Germany) has ably demonstrated this year. ... Another deal involving European biotech companies is the acquisition of the Austrian company

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics